Cellectis, a clinical-stage biotech company specializing in gene-editing therapies, announced it will report its financial results for the first quarter of 2026 on May 11, after the US market closes. The company, known for its allogeneic CAR T-cell therapies for cancer and gene therapy platforms, will publish the results on its website but will not hold a conference call. Investors can direct questions to the company's investor relations team. This update is important as it provides insight into the company's financial health and progress in its pioneering gene-editing treatments.
Solaris Energy Infrastructure (SEI) maintains a Buy rating with a new price target of $97, driven by strong growth from its Power Solutions segment and a 2.2GW contracted capacity with major tech clients. Its upcoming inclusion in the S&P SmallCap 60...
XRP Ledger's AI agents have completed over 1 million transactions but with low financial volume, indicating the AI economy is still in early stages. Bitcoin mining veteran Chandler Guo predicts Bitcoin will hit $120,000 within a year and $500,000 in ...
Argan, Inc. reported a strong first quarter for fiscal year 2027 with a 50% increase in revenue, reaching a record $290.9 million. This growth was fueled by multiple project completions and a robust $2.8 billion backlog, supported by rising energy de...
The Global X Russell 2000 Covered Call ETF (RYLD) provides a high monthly yield of 11.9% and achieved a 20.5% total return over the past year. However, its strategy involving at-the-money options causes structural net asset value (NAV) erosion and ca...
A Cambridge study found Ethereum's annual energy consumption at 7.87 gigawatt-hours, making it the second-least energy-intensive proof-of-stake (PoS) blockchain when adjusted for market value. This marks a significant improvement from its previous pr...
